Distinct patterns of protective antibodies are generated against Borrelia burgdorferi in mice experimentally inoculated with high and low doses of antigen.
We have studied the development of clinical arthritis and the generation of protective antibodies in two normal, inbred strains of mice either infected by ticks or experimentally (subcutaneous) inoculated with increasing numbers of Borrelia burgdorferi organisms. AKR/N mice developed only mild and DBA/2 mice only marginal clinical arthritis irrespective of the route of infection or the numbers of spirochetes (10-10(8)) inoculated. In contrast, immunodeficient SCID mice developed severe chronic arthritis under similar conditions, but with a delayed onset at lower numbers of needle-inoculated spirochetes or after tick bite. AKR/N and DBA/2 mice inoculated with either 10(4) (and fewer) B. burgdorferi organisms or via experimentally infected ticks generated antibodies with specificities for a variety of B. burgdorferi antigens except those to the outer surface proteins A and B (OspA, OspB). In contrast, mice inoculated with more than 10(4) spirochetes (10(5)-10(8)) developed in addition antibodies to OspA and OspB. Most notably, all three types of immune sera taken from DBA/2 mice showed similar capacities to confer protection on SCID mice against subsequent challenge with viable B. burgdorferi organisms. The data not only demonstrate that the quality of humoral immune responses to B. burgdorferi in mice is determined by the antigenic load, they also indicate the existence of further protective antibodies with specificities distinct from OspA and OspB.
Schaible
U E
UE
Max-Planck-Institut für Immunobiologie, Freiburg, Germany.
Gern
L
L
Wallich
R
R
Kramer
M D
MD
Prester
M
M
Simon
M M
MM
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000276:immunology; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007106:Immune Sera; D007114:Immunization; D007116:Immunization, Passive; D007121:Immunocompetence; D008074:Lipoproteins; D008193:Lyme Disease / Q000276:immunology*; D051379:Mice; D008806:Mice, Inbred AKR / Q000276:immunology; D008811:Mice, Inbred DBA / Q000276:immunology; D016513:Mice, SCID / Q000276:immunology; D016511:Severe Combined Immunodeficiency / Q000276:immunology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D007106:Immune Sera; D008074:Lipoproteins; C072045:OspA protein; C077030:OspB protein, Borrelia burgdorferi